Mednet Logo
CommunityNeurology

Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs?

In FRAIL-AF, participants were switched from VKA to dabigatran, rivaroxaban, apixaban, and edoxaban.
Community PollStarted

Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs?

124 physicians have voted

Join Mednetto vote and see how they answered.

4 Answers
Mednet Member
Mednet MemberInvited Expert
Cardiology · Weill Cornell Medical College of Cornell University
Answered on

I believe that apixaban carries a lower risk of bleeding, with particular reference to GI bleed, when compared to rivaroxaban and dabigatran. This is true in the population of AF patients at large and most probably in frail patients as well.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Neurology · University of Colorado, Climate & Health Dept
Answered on

From lowest to highest risk of intracranial and extracranial bleeding based on anecdotal experience:

apixaban < rivaroxaban < dabigatran < warfarin

I've never seen a patient on edoxaban.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Cardiology · Yale New Haven Hospital Heart And Vascular Center
Answered on

The prior evidence would suggest that not all NOACS have the same bleeding risk. More specifically, Apixaban appears to have a lower risk of GI bleeding than Rivaroxaban. While this is based on observational analyses, and head-to-head trials of non-generic medications are hard to come by, I have enc...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Cardiology · The George Washington University Hospital
Answered on

Apixiban, administered q 12 H, has the shortest half life, and would dissipate most rapidly if bleeding were to occur.

Join for free or sign in to see the full answer